OpenLB
Open Library of Bioscience
Advanced Search
Cell host & microbe
02 10, 2021;29 (2): 222-235.e4.

Induction of alarmin S100A8/A9 mediates activation of aberrant neutrophils in the pathogenesis of COVID-19.

Qirui Guo, Yingchi Zhao, Junhong Li, Jiangning Liu, Xiuhong Yang, Xuefei Guo, Ming Kuang, Huawei Xia, Zeming Zhang, Lili Cao, Yujie Luo, Linlin Bao, Xiao Wang, Xuemei Wei, Wei Deng, Nan Wang, Luoying Chen, Jingxuan Chen, Hua Zhu, Ran Gao, Chuan Qin, Xiangxi Wang, Fuping You
Author Information
  1. Qirui Guo: Institute of Systems Biomedicine, Department of Immunology, School of Basic Medical Sciences, Beijing Key Laboratory of Tumor Systems Biology, Peking University Health Science Center, Beijing, China.
  2. Yingchi Zhao: Institute of Systems Biomedicine, Department of Immunology, School of Basic Medical Sciences, Beijing Key Laboratory of Tumor Systems Biology, Peking University Health Science Center, Beijing, China.
  3. Junhong Li: University of Chinese Academy of Sciences, CAS Key Laboratory of Infection and Immunity, National Laboratory of Macromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China.
  4. Jiangning Liu: Key Laboratory of Human Disease Comparative Medicine, Chinese Ministry of Health, Beijing Key Laboratory for Animal Models of Emerging and Remerging Infectious Diseases, Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Comparative Medicine Center, Peking Union Medical College, Beijing, China.
  5. Xiuhong Yang: Key Laboratory of Human Disease Comparative Medicine, Chinese Ministry of Health, Beijing Key Laboratory for Animal Models of Emerging and Remerging Infectious Diseases, Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Comparative Medicine Center, Peking Union Medical College, Beijing, China.
  6. Xuefei Guo: Institute of Systems Biomedicine, Department of Immunology, School of Basic Medical Sciences, Beijing Key Laboratory of Tumor Systems Biology, Peking University Health Science Center, Beijing, China.
  7. Ming Kuang: Institute of Systems Biomedicine, Department of Immunology, School of Basic Medical Sciences, Beijing Key Laboratory of Tumor Systems Biology, Peking University Health Science Center, Beijing, China.
  8. Huawei Xia: Institute of Systems Biomedicine, Department of Immunology, School of Basic Medical Sciences, Beijing Key Laboratory of Tumor Systems Biology, Peking University Health Science Center, Beijing, China.
  9. Zeming Zhang: Institute of Systems Biomedicine, Department of Immunology, School of Basic Medical Sciences, Beijing Key Laboratory of Tumor Systems Biology, Peking University Health Science Center, Beijing, China.
  10. Lili Cao: Institute of Systems Biomedicine, Department of Immunology, School of Basic Medical Sciences, Beijing Key Laboratory of Tumor Systems Biology, Peking University Health Science Center, Beijing, China.
  11. Yujie Luo: Institute of Systems Biomedicine, Department of Immunology, School of Basic Medical Sciences, Beijing Key Laboratory of Tumor Systems Biology, Peking University Health Science Center, Beijing, China.
  12. Linlin Bao: Key Laboratory of Human Disease Comparative Medicine, Chinese Ministry of Health, Beijing Key Laboratory for Animal Models of Emerging and Remerging Infectious Diseases, Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Comparative Medicine Center, Peking Union Medical College, Beijing, China.
  13. Xiao Wang: Institute of Systems Biomedicine, Department of Immunology, School of Basic Medical Sciences, Beijing Key Laboratory of Tumor Systems Biology, Peking University Health Science Center, Beijing, China.
  14. Xuemei Wei: Institute of Systems Biomedicine, Department of Immunology, School of Basic Medical Sciences, Beijing Key Laboratory of Tumor Systems Biology, Peking University Health Science Center, Beijing, China.
  15. Wei Deng: Key Laboratory of Human Disease Comparative Medicine, Chinese Ministry of Health, Beijing Key Laboratory for Animal Models of Emerging and Remerging Infectious Diseases, Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Comparative Medicine Center, Peking Union Medical College, Beijing, China.
  16. Nan Wang: University of Chinese Academy of Sciences, CAS Key Laboratory of Infection and Immunity, National Laboratory of Macromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China.
  17. Luoying Chen: Institute of Systems Biomedicine, Department of Immunology, School of Basic Medical Sciences, Beijing Key Laboratory of Tumor Systems Biology, Peking University Health Science Center, Beijing, China.
  18. Jingxuan Chen: Institute of Systems Biomedicine, Department of Immunology, School of Basic Medical Sciences, Beijing Key Laboratory of Tumor Systems Biology, Peking University Health Science Center, Beijing, China.
  19. Hua Zhu: Key Laboratory of Human Disease Comparative Medicine, Chinese Ministry of Health, Beijing Key Laboratory for Animal Models of Emerging and Remerging Infectious Diseases, Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Comparative Medicine Center, Peking Union Medical College, Beijing, China.
  20. Ran Gao: Key Laboratory of Human Disease Comparative Medicine, Chinese Ministry of Health, Beijing Key Laboratory for Animal Models of Emerging and Remerging Infectious Diseases, Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Comparative Medicine Center, Peking Union Medical College, Beijing, China.
  21. Chuan Qin: Key Laboratory of Human Disease Comparative Medicine, Chinese Ministry of Health, Beijing Key Laboratory for Animal Models of Emerging and Remerging Infectious Diseases, Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Comparative Medicine Center, Peking Union Medical College, Beijing, China. Electronic address: qinchuan@pumc.edu.cn.
  22. Xiangxi Wang: University of Chinese Academy of Sciences, CAS Key Laboratory of Infection and Immunity, National Laboratory of Macromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China. Electronic address: xiangxi@ibp.ac.cn.
  23. Fuping You: Institute of Systems Biomedicine, Department of Immunology, School of Basic Medical Sciences, Beijing Key Laboratory of Tumor Systems Biology, Peking University Health Science Center, Beijing, China. Electronic address: fupingyou@hsc.pku.edu.cn.
PMID: 33388094 DOI: 10.1016/j.chom.2020.12.016

Abstract

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic poses an unprecedented public health crisis. Evidence suggests that SARS-CoV-2 infection causes dysregulation of the immune system. However, the unique signature of early immune responses remains elusive. We characterized the transcriptome of rhesus macaques and mice infected with SARS-CoV-2. Alarmin S100A8 was robustly induced in SARS-CoV-2-infected animal models as well as in COVID-19 patients. Paquinimod, a specific inhibitor of S100A8/A9, could rescue the pneumonia with substantial reduction of viral loads in SARS-CoV-2-infected mice. Remarkably, Paquinimod treatment resulted in almost 100% survival in a lethal model of mouse coronavirus infection using the mouse hepatitis virus (MHV). A group of neutrophils that contributes to the uncontrolled pathological damage and onset of COVID-19 was dramatically induced by coronavirus infection. Paquinimod treatment could reduce these neutrophils and regain anti-viral responses, unveiling key roles of S100A8/A9 and aberrant neutrophils in the pathogenesis of COVID-19, highlighting new opportunities for therapeutic intervention.

Keywords

Paquinimod S100A8/A9 SARS-CoV-2 aberrant neutrophils

References

Circ Heart Fail. 2017 Nov;10(11): [PMID: 29158436]
Proc Natl Acad Sci U S A. 2002 Jun 11;99(12):8289-94 [PMID: 12060772]
Infect Control Hosp Epidemiol. 2020 Sep;41(9):1124-1125 [PMID: 32317036]
Nat Med. 2004 Nov;10(11):1216-21 [PMID: 15502843]
Curr Allergy Asthma Rep. 2018 Sep 28;18(11):63 [PMID: 30267163]
Cell Death Differ. 2020 Dec;27(12):3209-3225 [PMID: 33037393]
Ann Rheum Dis. 2015 Dec;74(12):2254-8 [PMID: 25969431]
Nature. 2020 Mar;579(7798):265-269 [PMID: 32015508]
Int J Mol Sci. 2016 May 05;17(5): [PMID: 27164085]
PLoS Biol. 2009 Apr 28;7(4):e97 [PMID: 19402754]
PLoS One. 2020 Jul 9;15(7):e0235458 [PMID: 32645044]
Cell Host Microbe. 2016 Feb 10;19(2):181-93 [PMID: 26867177]
Heliyon. 2020 Sep;6(9):e05116 [PMID: 33015402]
N Engl J Med. 2020 Feb 20;382(8):727-733 [PMID: 31978945]
Nat Commun. 2019 Apr 23;10(1):1916 [PMID: 31015489]
J Clin Invest. 2012 Aug;122(8):2711-9 [PMID: 22850880]
Am J Sports Med. 2018 Mar;46(3):671-678 [PMID: 29190116]
Nat Med. 2020 Jun;26(6):842-844 [PMID: 32398875]
Exp Biol Med (Maywood). 2017 Apr;242(8):859-873 [PMID: 27895095]
Apoptosis. 2016 Mar;21(3):329-39 [PMID: 26612514]
mBio. 2015 May 26;6(3):e00638-15 [PMID: 26015500]
Nature. 2002 Dec 19-26;420(6917):846-52 [PMID: 12490957]
Infect Genet Evol. 2020 Nov;85:104587 [PMID: 33039603]
Immunol Rev. 2017 Nov;280(1):41-56 [PMID: 29027222]
Virol Sin. 2014 Dec;29(6):393-402 [PMID: 25547683]
J Clin Invest. 2019 Apr 16;129(7):2872-2877 [PMID: 30990798]
Bioinformatics. 2012 Nov 1;28(21):2782-8 [PMID: 22923299]
Nat Immunol. 2013 Dec;14(12):1237-46 [PMID: 24185615]
Curr Opin Immunol. 2005 Aug;17(4):359-65 [PMID: 15955682]
J Leukoc Biol. 2013 May;93(5):761-9 [PMID: 23475575]
J Immunol. 2015 Jun 1;194(11):5539-48 [PMID: 25911757]
Nat Immunol. 2014 Jul;15(7):602-11 [PMID: 24940954]
Cell Metab. 2013 May 7;17(5):695-708 [PMID: 23663738]
Nucleic Acids Res. 2019 May 7;47(8):e47 [PMID: 30783653]
Signal Transduct Target Ther. 2020 Mar 27;5(1):33 [PMID: 32296069]
Nat Med. 2007 Sep;13(9):1042-9 [PMID: 17767165]
J Leukoc Biol. 2021 Jan;109(1):67-72 [PMID: 32869342]
Cell. 2006 Feb 24;124(4):783-801 [PMID: 16497588]
J Virol. 2010 Nov;84(21):11297-309 [PMID: 20702617]
Cell Mol Immunol. 2020 May;17(5):533-535 [PMID: 32203188]
Nat Med. 2020 Jul;26(7):1070-1076 [PMID: 32514174]
Nature. 2020 Jul;583(7818):830-833 [PMID: 32380511]
Lancet. 2020 Feb 15;395(10223):497-506 [PMID: 31986264]
Front Immunol. 2020 May 01;11:827 [PMID: 32425950]
Arthritis Rheumatol. 2017 Mar;69(3):655-667 [PMID: 27696751]
Nat Rev Immunol. 2010 Dec;10(12):826-37 [PMID: 21088683]
Sci Immunol. 2020 Jul 15;5(49): [PMID: 32669287]
PLoS Pathog. 2010 Apr 08;6(4):e1000849 [PMID: 20386712]
Mol Aspects Med. 2014 Dec;40:1-116 [PMID: 25010388]
Front Immunol. 2017 Nov 13;8:1493 [PMID: 29180999]
Cell. 2020 Sep 17;182(6):1419-1440.e23 [PMID: 32810438]
Cell. 2020 Sep 17;182(6):1401-1418.e18 [PMID: 32810439]
JCI Insight. 2020 Jun 4;5(11): [PMID: 32329756]
Nat Immunol. 2020 Sep;21(9):1119-1133 [PMID: 32719519]
Cell. 2020 May 28;181(5):1036-1045.e9 [PMID: 32416070]
JAMA Intern Med. 2020 Jul 1;180(7):934-943 [PMID: 32167524]
Front Immunol. 2018 Jun 11;9:1298 [PMID: 29942307]
Clin Infect Dis. 2020 Sep 12;71(6):1400-1409 [PMID: 32270184]
Cell Mol Immunol. 2020 May;17(5):541-543 [PMID: 32203186]
J Leukoc Biol. 2007 Jan;81(1):1-5 [PMID: 17032697]
Clin Chim Acta. 2004 Jun;344(1-2):37-51 [PMID: 15149869]
Immunity. 2017 Jan 17;46(1):15-28 [PMID: 28099862]
Science. 2020 Aug 7;369(6504):718-724 [PMID: 32661059]
Microbes Infect. 2013 Feb;15(2):88-95 [PMID: 23123977]

MeSH Term

Alarmins
Animals
Antiviral Agents
COVID-19
Disease Models, Animal
Female
Humans
Macaca mulatta
Male
Mice
Mice, Inbred C57BL
Mice, Knockout
Neutrophils
SARS-CoV-2
Transcriptome
Viral Load
COVID-19 Drug Treatment

Chemicals

Alarmins
Antiviral Agents
Journal Article Research Support, Non-U.S. Gov't

Word Cloud

Similar Articles

Cited By